Showing results (1991-2000 of 2,046) with videos related to
Sort By:
Pageof 205
Journal of the Pediatric Infectious Diseases Society|October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.Scientific Reports|June 4, 2021
Sleep duration and napping in relation to colorectal and gastric cancer in the MCC-Spain studyKyriaki Papantoniou, Gemma Castaño-Vinyals, Ana Espinosa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2019
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy ResistanceAlex Pearson, Paula Proszek, Javier Pascual, et al.Elife|July 19, 2017
A connectome of a learning and memory center in the adult Drosophila brainShin-Ya Takemura, Yoshinori Aso, Toshihide Hige, et al.Journal of Clinical Medicine|August 27, 2021
Supervised Machine Learning Approach to Identify Early Predictors of Poor Outcome in Patients with COVID-19 Presenting to a Large Quaternary Care Hospital in New York CityJason Zucker, Angela Gomez-Simmonds, Lawrence J Purpura, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2022
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancerN C Turner, C Swift, B Jenkins, et al.Journal of Medicinal Chemistry|May 28, 2004
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent K(ATP) opener that selectively inhibits spontaneous bladder contractionsWilliam A Carroll, Robert J Altenbach, Hao Bai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO StudyNicholas C Turner, Judith Balmaña, Coralie Poncet, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker ResultsPeter Schmid, Nicholas C Turner, Carlos H Barrios, et al.The Lancet. Oncology|July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trialNicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.Pageof 205